In conclusion, we found that CD19 cell count at baseline could influence B cell kinetics; indeed, our findings revealed that a considerable proportion of MS patients did not achieve a complete CD19 cell depletion and these patients had a higher baseline CD19 cell count. The gene discussed is CD19; the disease is myeloid sarcoma.